- Sarepta says it won’t comply with FDA request to stop shipping gene therapy Elevidys Reuters
- Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys The New York Times
- Sarepta shares plunge 40% as future of its gene therapy appears at risk CNBC
- Third death from a Sarepta gene therapy biocentury.com
- We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress statnews.com
Source link